X0303 4 2010-10-27 0 0001338042 Aegerion Pharmaceuticals, Inc. AEGR 0001257444 ALTA BIOPHARMA PARTNERS III LP ONE EMBARCADERO CENTER SUITE 3700 CA 94111 0 0 1 0 0001280234 ALTA BIOPHARMA MANAGEMENT III LLC ONE EMBARCADERO CENTER SUITE 3700 CA 94111 0 0 1 0 0001280265 ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG ONE EMBARCADERO CENTER SUITE 3700 CA 94111 0 0 1 0 0001280238 ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC ONE EMBARCADERO CENTER SUITE 3700 CA 94111 0 0 1 0 0001198323 DELEAGE JEAN ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO CA 94111 0 0 1 0 0001198321 CHAMPSI FARAH ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO CA 94132 0 0 1 0 0001198332 PENHOET EDWARD ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO CA 94111 0 0 1 0 0001211840 HURWITZ EDWARD ONE EMBARCADERO CENTER, SUITE 3700 SAN FRANCISCO CA 94111 0 0 1 0 Common Stock 2010-10-27 4 C 0 1086336 A 1086336 D Common Stock 2010-10-27 4 C 0 379545 A 1465881 D Common Stock 2010-10-27 4 C 0 700050 7.60 A 2165931 D Common Stock 2010-10-27 4 P 0 289236 9.50 A 2455167 D Common Stock 2010-10-27 4 C 0 72957 A 72957 D Common Stock 2010-10-27 4 C 0 25490 A 98447 D Common Stock 2010-10-27 4 C 0 47010 7.60 A 145457 D Common Stock 2010-10-27 4 P 0 19425 9.50 A 164882 D Common Stock 2010-10-27 4 C 0 26771 A 26771 D Common Stock 2010-10-27 4 C 0 9353 A 36124 D Common Stock 2010-10-27 4 C 0 17250 7.60 A 53374 D Common Stock 2010-10-27 4 P 0 7128 9.50 A 60502 D Series A Convertible Prefered Stock 2010-10-27 4 C 0 2806991 0.00 D Common Stock 1086336 0 D Series A Convertible Prefered Stock 2010-10-27 4 C 0 188514 0.00 D Common Stock 72957 0 D Series A Convertible Prefered Stock 2010-10-27 4 C 0 69176 0.00 D Common Stock 26771 0 D Series B Convertible Preferred Stock 2010-10-27 4 C 0 621923 0.00 D Common Stock 379545 0 D Series B Convertible Preferred Stock 2010-10-27 4 C 0 41768 0.00 D Common Stock 25490 0 D Series B Convertible Preferred Stock 2010-10-27 4 C 0 15327 0.00 D Common Stock 9353 0 D Senior Subordinated Convertible Promissory Notes 7.60 2010-10-27 4 C 0 5320408.54 0.00 D 2011-12-31 Common Stock 700050 0.00 D Senior Subordinated Convertible Promissory Notes 7.60 2010-10-27 4 C 0 357311.91 0.00 D 2011-12-31 Common Stock 47010 0.00 D Senior Subordinated Convertible Promissory Notes 7.60 2010-10-27 4 C 0 131117.33 0.00 D 2011-12-31 Common Stock 17250 0.00 D Upon the closing of the Issuer's initial public offering on October 27, 2010, each share of Series A Convertible Preferred Stock (the "Series A Shares"), plus accrued dividends, automatically converted into shares of common stock of the Issuer in accordance with the terms of the Issuer's Third Amended and Restated Certificate of Incorporation. Each Series A Share converted into 0.38701117412 shares of common stock. Alta BioPharma Management III, LLC ("ABMIII") is the general partner of ABPIII and the managing limited partner of Alta BioPharma Partners III GmbH & Co. Beteiligungs KG ("ABPIIIKG"). Jean Deleage, Farah Champsi, Edward Penhoet and Edward Hurwitz are the directors of ABMIII and managers of Alta Embarcadero BioPharma Partners III, LLC ("AEBPIII"). Alison Kiley, a director of the Issuer, is a member of ABMIII and may be deemed to share investment power over the securities of the Issuer held by ABPIII, ABPIIIKG and AEBPIII with the directors of ABMIII and managers of AEBPIII. Each of Dr. Deleage, Ms. Champsi, Dr. Penhoet and Mr. Hurwitz disclaim beneficial ownership of such securities except to the extent of his or her pecuniary interest therein. These securities are owned directly by ABPIII. Upon the closing of the Issuer's initial public offering on October 27, 2010, each share of Series B Convertible Preferred Stock (the "Series B Shares"), plus accrued dividends, automatically converted into shares of common stock of the Issuer in accordance with the terms of the Issuer's Third Amended and Restated Certificate of Incorporation. Each Series B Share converted into 0.61027657931 basis of common stock. The outstanding principal and accrued and unpaid interest on these Convertible Notes was automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering at $7.60 per share, which is equal to 80% of the Issuer's initial public offering price per share. These securities are owned directly by ABPIIIKG. These securities are owned directly by AEBPIII. The Series A Shares were convertible at any time, at the holder's election, and automatically upon consummation of the Issuer's initial public offering and had no expiration date. The Series B Shares were convertible at any time, at the holder's election, and automatically upon consummation of the Issuer's initial public offering and had no expiration date. The Convertible Notes were issued on September 2, 2008, December 11, 2008, July 2, 2009, January 28, 2010, June 14, 2010, August 13, 2010 and October 1, 2010. Any outstanding principal amount and accrued but unpaid interest thereon was automatically convertible into shares of capital stock of the Issuer upon the consummation of specified sale transactions involving the securities of the Issuer, including an initial public offering of the Issuer's common stock meeting certain conditions. By Alta BioPharma Management Partners III, LLC /s/ Jean Deleage, Director 2010-10-27 /s/ Jean Deleage, Director 2010-10-27 by Alta BioPharma Management Partners III, LLC /s/ Jean Deleage, Director 2010-10-27 /s/ Jean Deleage, Manager 2010-10-27 /s/ Jean Deleage 2010-10-27 /s/ Farah Champsi 2010-10-27 /s/ Edward Penhoet 2010-10-27 /s/ Edward Hurwitz 2010-10-27